Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer

Trial Profile

Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Veliparib (Primary) ; Cisplatin; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 22 Jan 2016 Status changed from active, no longer recruiting to completed, according to results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 22 Jan 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 05 Mar 2015 According to the ClinicalTrials.gov record, planned end date changed to 1 Feb 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top